Zymeworks CEO on why the Theravance deal is value for money

Kenneth Galbraith, Zymeworks CEO June 29, 2026 11:51 AM EDTUpdated June 30, 05:48 AM Deals Zymeworks CEO on why the Ther­a­vance deal is val­ue for mon­ey Elizabeth Cairns Senior biopharma journalist On the face of it, near­ly $1 bil­lion seems like a lot to spend on a biotech like Ther­a­vance. The com­pa­ny was clear­ly run­ning out … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER